David S. Wise Sells 1,500 Shares of LivaNova PLC (LIVN) Stock
LivaNova PLC (NASDAQ:LIVN) insider David S. Wise sold 1,500 shares of the stock in a transaction on Thursday, November 15th. The shares were sold at an average price of $119.23, for a total value of $178,845.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
NASDAQ LIVN opened at $120.16 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.21 and a current ratio of 1.65. LivaNova PLC has a 1 year low of $76.14 and a 1 year high of $131.54. The firm has a market capitalization of $6.11 billion, a P/E ratio of 36.30, a PEG ratio of 3.77 and a beta of 0.94.
LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, October 31st. The company reported $0.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.08). LivaNova had a negative net margin of 8.31% and a positive return on equity of 8.77%. The firm had revenue of $272.10 million during the quarter, compared to analyst estimates of $275.03 million. During the same period in the previous year, the company earned $0.83 earnings per share. LivaNova’s revenue was up 8.3% on a year-over-year basis. On average, analysts expect that LivaNova PLC will post 3.1 earnings per share for the current fiscal year.
Several analysts have recently commented on LIVN shares. Stifel Nicolaus increased their price objective on LivaNova from $115.00 to $130.00 and gave the company a “buy” rating in a report on Tuesday, July 24th. BidaskClub upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 26th. Needham & Company LLC reiterated a “buy” rating and set a $135.00 price objective (up previously from $128.00) on shares of LivaNova in a report on Wednesday, August 1st. Zacks Investment Research lowered LivaNova from a “buy” rating to a “hold” rating in a report on Thursday, September 20th. Finally, Jefferies Financial Group increased their price objective on LivaNova to $150.00 and gave the company a “buy” rating in a report on Tuesday, October 2nd. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and two have issued a strong buy rating to the company. LivaNova presently has a consensus rating of “Buy” and a consensus price target of $126.50.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Further Reading: Investing strategies using the yield curve
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.